{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T07:47:47Z","timestamp":1781855267078,"version":"3.54.5"},"reference-count":66,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009379","name":"Interdisziplin\u00e4res Zentrum f\u00fcr Klinische Forschung, Universit\u00e4tsklinikum W\u00fcrzburg","doi-asserted-by":"publisher","award":["BD247"],"award-info":[{"award-number":["BD247"]}],"id":[{"id":"10.13039\/501100009379","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicology and Applied Pharmacology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.taap.2025.117625","type":"journal-article","created":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:04:49Z","timestamp":1761869089000},"page":"117625","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["An intestinal matrix-based human lung cancer model reflects clinical data from gefitinib on dosage-dependent efficacy"],"prefix":"10.1016","volume":"506","author":[{"given":"Elena Johanna","family":"Weigl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thorsten","family":"Walles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Nietzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gudrun","family":"Dandekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heike","family":"Walles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Goettlich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"14","key":"10.1016\/j.taap.2025.117625_bb0005","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1016\/S0960-894X(01)00344-4","article-title":"Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer","volume":"11","author":"Barker","year":"2001","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"1","key":"10.1016\/j.taap.2025.117625_bb0010","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12010028","article-title":"Connecting cancer pathways to tumor engines: a stratification tool for colorectal cancer combining human in vitro tissue models with Boolean in silico models","volume":"12","author":"Baur","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.taap.2025.117625_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2020.119766","article-title":"Matrix decoded - a pancreatic extracellular matrix with organ specific cues guiding human iPSC differentiation","volume":"244","author":"Berger","year":"2020","journal-title":"Biomaterials"},{"issue":"1\u20132","key":"10.1016\/j.taap.2025.117625_bb0020","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1159\/000084509","article-title":"Invasion and metastasis in colorectal cancer: epithelial-mesenchymal transition, mesenchymal-epithelial transition, stem cells and beta-catenin","volume":"179","author":"Brabletz","year":"2005","journal-title":"Cells Tissues Organs"},{"issue":"16","key":"10.1016\/j.taap.2025.117625_bb0025","doi-asserted-by":"crossref","first-page":"3029","DOI":"10.1002\/cncr.33587","article-title":"The ever-increasing importance of cancer as a leading cause of premature death worldwide","volume":"127","author":"Bray","year":"2021","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.taap.2025.117625_bb0030","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"issue":"2","key":"10.1016\/j.taap.2025.117625_bb0035","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/35000025","article-title":"The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression","volume":"2","author":"Cano","year":"2000","journal-title":"Nat. Cell Biol."},{"issue":"4","key":"10.1016\/j.taap.2025.117625_bb0040","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1158\/1078-0432.CCR-03-0564","article-title":"United States Food and Drug Administration drug approval summary: Gefitinib (ZD1839; Iressa) tablets","volume":"10","author":"Cohen","year":"2004","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.taap.2025.117625_bb0045","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1021\/acsbiomaterials.9b00161","article-title":"Effects of culture condition on epigenomic profiles of brain tumor cells","volume":"5","author":"Cox","year":"2019","journal-title":"ACS Biomater. Sci. Eng."},{"issue":"4","key":"10.1016\/j.taap.2025.117625_bb0050","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.coph.2010.05.001","article-title":"Efficacy of anti-cancer agents in cell lines versus human primary tumour tissue","volume":"10","author":"Cree","year":"2010","journal-title":"Curr. Opin. Pharmacol."},{"issue":"2","key":"10.1016\/j.taap.2025.117625_bb0055","article-title":"Acquired resistance to third-generation EGFR-TKIs and emerging next-generation EGFR inhibitors","volume":"2","author":"Du","year":"2021","journal-title":"Innovation (Cambridge (Mass))"},{"issue":"7","key":"10.1016\/j.taap.2025.117625_bb0060","doi-asserted-by":"crossref","DOI":"10.3390\/cells12071001","article-title":"Cancer spheroids and organoids as novel tools for research and therapy: state of the art and challenges to guide precision medicine","volume":"12","author":"El Harane","year":"2023","journal-title":"Cells"},{"issue":"8","key":"10.1016\/j.taap.2025.117625_bb0065","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0160282","article-title":"Human Organotypic lung tumor models: suitable for preclinical 18F-FDG PET-imaging","volume":"11","author":"Fecher","year":"2016","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.taap.2025.117625_bb0070","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1097\/01.cad.0000224445.23953.d9","article-title":"Effect of culture conditions on the chemosensitivity of ovarian cancer cell lines","volume":"17","author":"Fernando","year":"2006","journal-title":"Anti-Cancer Drugs"},{"issue":"5","key":"10.1016\/j.taap.2025.117625_bb0075","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1634\/theoncologist.7-5-401","article-title":"Clinical trial design for target-based therapy","volume":"7","author":"Fox","year":"2002","journal-title":"Oncologist"},{"issue":"7","key":"10.1016\/j.taap.2025.117625_bb0080","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.3727\/096504018X15151523767752","article-title":"A retrospective comparison of the clinical efficacy of Gefitinib, Erlotinib, and Afatinib in Japanese patients with non-small cell lung cancer","volume":"26","author":"Fujiwara","year":"2018","journal-title":"Oncol. Res."},{"issue":"12","key":"10.1016\/j.taap.2025.117625_bb0085","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1200\/JCO.2003.10.038","article-title":"Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (the IDEAL 1 trial) [corrected]","volume":"21","author":"Fukuoka","year":"2003","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.taap.2025.117625_bb0090","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1038\/s41598-020-79325-8","article-title":"Polysaccharide hydrogel based 3D printed tumor models for chemotherapeutic drug screening","volume":"11","author":"Gebeyehu","year":"2021","journal-title":"Sci. Rep."},{"issue":"10","key":"10.1016\/j.taap.2025.117625_bb0095","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12102727","article-title":"Promising applications of tumor spheroids and organoids for personalized medicine","volume":"12","author":"Gilazieva","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.taap.2025.117625_bb0100","article-title":"A combined 3D tissue engineered in vitro\/in silico lung tumor model for predicting drug effectiveness in specific mutational backgrounds","volume":"110","author":"G\u00f6ttlich","year":"2016","journal-title":"J. Visual. Exp. JoVE"},{"issue":"8","key":"10.1016\/j.taap.2025.117625_bb0105","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1002\/1878-0261.12323","article-title":"A combined tissue-engineered\/in silico signature tool patient stratification in lung cancer","volume":"12","author":"G\u00f6ttlich","year":"2018","journal-title":"Mol. Oncol."},{"issue":"18","key":"10.1016\/j.taap.2025.117625_bb0110","doi-asserted-by":"crossref","first-page":"3815","DOI":"10.1200\/JCO.2002.03.038","article-title":"Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial","volume":"20","author":"Herbst","year":"2002","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.taap.2025.117625_bb0115","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.625","article-title":"Nuances to precision dosing strategies of targeted cancer medicines","volume":"8","author":"Hopkins","year":"2020","journal-title":"Pharmacol. Res. Perspect."},{"issue":"5","key":"10.1016\/j.taap.2025.117625_bb0120","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.apsb.2015.07.001","article-title":"Mechanisms of resistance to EGFR tyrosine kinase inhibitors","volume":"5","author":"Huang","year":"2015","journal-title":"Acta Pharm. Sin. B"},{"issue":"2","key":"10.1016\/j.taap.2025.117625_bb0125","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1002\/jcp.21223","article-title":"Epithelial\u2013 mesenchymal and mesenchymal \u2013 epithelial transitions in carcinoma progression","volume":"213","author":"Hugo","year":"2007","journal-title":"J. Cell. Physiol."},{"issue":"4","key":"10.1016\/j.taap.2025.117625_bb0130","doi-asserted-by":"crossref","DOI":"10.1038\/oncsis.2017.17","article-title":"MET amplification and epithelial-to-mesenchymal transition exist as parallel resistance mechanisms in erlotinib-resistant, EGFR-mutated, NSCLC HCC827 cells","volume":"6","author":"Jakobsen","year":"2017","journal-title":"Oncogenesis"},{"issue":"5","key":"10.1016\/j.taap.2025.117625_bb0135","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s00280-019-03788-4","article-title":"Gefitinib exposure and occurrence of interstitial lung disease in Japanese patients with non-small-cell lung cancer","volume":"83","author":"Kawata","year":"2019","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.taap.2025.117625_bb0140","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.lungcan.2021.02.026","article-title":"The evolving landscape of biomarker testing for non-small cell lung cancer in Europe","volume":"154","author":"Kerr","year":"2021","journal-title":"Lung Cancer (Amsterdam, Netherlands)"},{"issue":"2","key":"10.1016\/j.taap.2025.117625_bb0145","first-page":"289","article-title":"Modular micro-physiological human tumor\/tissue models based on decellularized tissue for improved preclinical testing","volume":"38","author":"K\u00fchnemundt","year":"2020","journal-title":"Altex"},{"issue":"1","key":"10.1016\/j.taap.2025.117625_bb0150","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s12964-023-01082-8","article-title":"Toward the next generation EGFR inhibitors: an overview of osimertinib resistance mediated by EGFR mutations in non-small cell lung cancer","volume":"21","author":"Li","year":"2023","journal-title":"Cell Commun. Signal."},{"key":"10.1016\/j.taap.2025.117625_bb0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2023.115697","article-title":"A fully validated method for simultaneous determination of icotinib, osimertinib, gefitinib and O-desmethyl gefitinib in human plasma using UPLC-MS\/MS for therapeutic drug monitoring","volume":"236","author":"Li","year":"2023","journal-title":"J. Pharm. Biomed. Anal."},{"issue":"11","key":"10.1016\/j.taap.2025.117625_bb0160","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1089\/ten.2006.0388","article-title":"Engineered liver-like tissue on a capillarized matrix for applied research","volume":"13","author":"Linke","year":"2007","journal-title":"Tissue Eng."},{"issue":"4","key":"10.1016\/j.taap.2025.117625_bb0165","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24044113","article-title":"Optimization of primary human bronchial epithelial 3D cell culture with donor-matched fibroblasts and comparison of two different culture media","volume":"24","author":"Maurer","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"10","key":"10.1016\/j.taap.2025.117625_bb0170","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMoa0810699","article-title":"Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma","volume":"361","author":"Mok","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.taap.2025.117625_bb0175","article-title":"Tissue engineering of a human 3D in vitro tumor test system","volume":"78","author":"Moll","year":"2013","journal-title":"J. Visual. Exp. JoVE"},{"issue":"3","key":"10.1016\/j.taap.2025.117625_bb0180","doi-asserted-by":"crossref","first-page":"171","DOI":"10.12793\/tcp.2021.29.e17","article-title":"Pharmacokinetic properties and bioequivalence of gefitinib 250 mg in healthy Korean male subjects","volume":"29","author":"Moon","year":"2021","journal-title":"Transl. Clin. Pharmacol."},{"issue":"11","key":"10.1016\/j.taap.2025.117625_bb0185","doi-asserted-by":"crossref","DOI":"10.3390\/cells7110212","article-title":"Mechanism of resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and a potential treatment strategy","volume":"7","author":"Nagano","year":"2018","journal-title":"Cells"},{"key":"10.1016\/j.taap.2025.117625_bb0190","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1146\/annurev.cellbio.22.010305.104315","article-title":"Of extracellular matrix, scaffolds, and signaling: tissue architecture regulates development, homeostasis, and cancer","volume":"22","author":"Nelson","year":"2006","journal-title":"Annu. Rev. Cell Dev. Biol."},{"issue":"7","key":"10.1016\/j.taap.2025.117625_bb0195","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1089\/ten.tec.2015.0557","article-title":"Mimicking metastases including tumor stroma: a new technique to generate a three-dimensional colorectal cancer model based on a biological decellularized intestinal scaffold","volume":"22","author":"Nietzer","year":"2016","journal-title":"Tissue Eng. Part C Methods"},{"key":"10.1016\/j.taap.2025.117625_bb0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.mtla.2025.102440","article-title":"A fully human in-vitro model for bone metastasis: potential of an electrospun scaffold as alternative to biological materials for osteoblast\/osteoclast differentiation","volume":"42","author":"Nieves","year":"2025","journal-title":"Materialia"},{"issue":"1","key":"10.1016\/j.taap.2025.117625_bb0205","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1186\/s12890-022-02249-8","article-title":"Pharmacokinetics of gefitinib in elderly patients with EGFR-mutated advanced non-small cell lung cancer: a prospective study","volume":"22","author":"Nio","year":"2022","journal-title":"BMC Pulm. Med."},{"issue":"Pt 1","key":"10.1016\/j.taap.2025.117625_bb0210","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.semcancer.2017.11.019","article-title":"Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): moving from targeted therapy to immunotherapy","volume":"52","author":"Osmani","year":"2018","journal-title":"Semin. Cancer Biol."},{"issue":"5676","key":"10.1016\/j.taap.2025.117625_bb0215","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1126\/science.1099314","article-title":"EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy","volume":"304","author":"Paez","year":"2004","journal-title":"Science (New York, N.Y.)"},{"issue":"9","key":"10.1016\/j.taap.2025.117625_bb0220","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14092176","article-title":"EMT, stemness, and drug resistance in biological context: a 3D tumor tissue\/in silico platform for analysis of combinatorial treatment in NSCLC with aggressive KRAS-biomarker signatures","volume":"14","author":"Peindl","year":"2022","journal-title":"Cancers"},{"issue":"21","key":"10.1016\/j.taap.2025.117625_bb0225","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232113306","article-title":"Comparison of EMT-related and multi-drug resistant gene expression, extracellular matrix production, and drug sensitivity in NSCLC spheroids generated by scaffold-free and scaffold-based methods","volume":"23","author":"Qi","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.taap.2025.117625_bb0230","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1081\/CNV-120000374","article-title":"Order and disorder: the role of extracellular matrix in epithelial cancer","volume":"20","author":"Radisky","year":"2002","journal-title":"Cancer Investig."},{"issue":"4\u20135","key":"10.1016\/j.taap.2025.117625_bb0235","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.addr.2011.05.001","article-title":"In vitro human tissue models \u2013 moving towards personalized regenerative medicine","volume":"63","author":"Schenke-Layland","year":"2011","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"1","key":"10.1016\/j.taap.2025.117625_bb0240","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1097\/01.ju.0000145882.80339.18","article-title":"Biological vascularized matrix for bladder tissue engineering: matrix preparation, reseeding technique and short-term implantation in a porcine model","volume":"173","author":"Schultheiss","year":"2005","journal-title":"J. Urol."},{"issue":"2","key":"10.1016\/j.taap.2025.117625_bb0245","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/labinvest.2013.147","article-title":"Epidermal growth factor receptor mutations in lung adenocarcinoma","volume":"94","author":"Siegelin","year":"2014","journal-title":"Lab. Investig. J. Tech. Methods Pathol."},{"issue":"8\u20139","key":"10.1016\/j.taap.2025.117625_bb0250","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1290\/0604027.1","article-title":"Life isn\u2019t flat: taking cancer biology to the next dimension","volume":"42","author":"Smalley","year":"2006","journal-title":"In Vitro Cell. Dev. Biol. Anim."},{"issue":"2","key":"10.1016\/j.taap.2025.117625_bb0255","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.molonc.2013.11.009","article-title":"Establishment of a human 3D lung cancer model based on a biological tissue matrix combined with a Boolean in silico model","volume":"8","author":"Stratmann","year":"2014","journal-title":"Mol. Oncol."},{"issue":"1","key":"10.1016\/j.taap.2025.117625_bb0260","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000676","article-title":"Inhibition of TGF-\u03b2-receptor signaling augments the antitumor function of ROR1-specific CAR T-cells against triple-negative breast cancer","volume":"8","author":"St\u00fcber","year":"2020","journal-title":"J. Immunother. Cancer"},{"issue":"19","key":"10.1016\/j.taap.2025.117625_bb0265","doi-asserted-by":"crossref","first-page":"5659","DOI":"10.1158\/1078-0432.CCR-06-0368","article-title":"Monitoring tumor glucose utilization by positron emission tomography for the prediction of treatment response to epidermal growth factor receptor kinase inhibitors","volume":"12","author":"Su","year":"2006","journal-title":"Clin. Cancer Res."},{"issue":"11","key":"10.1016\/j.taap.2025.117625_bb0270","doi-asserted-by":"crossref","DOI":"10.3390\/jpm11111102","article-title":"Diagnostic, predictive, and prognostic biomarkers in non-small cell lung cancer (NSCLC) Management","volume":"11","author":"\u0160uti\u0107","year":"2021","journal-title":"J. Personal. Med."},{"issue":"9496","key":"10.1016\/j.taap.2025.117625_bb0275","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1016\/S0140-6736(05)67625-8","article-title":"Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa survival evaluation in lung Cancer)","volume":"366","author":"Thatcher","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.taap.2025.117625_bb0280","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.semcdb.2022.12.007","article-title":"Apical-basal polarity in the gut","volume":"150-151","author":"Thottacherry","year":"2023","journal-title":"Semin. Cell Dev. Biol."},{"issue":"1","key":"10.1016\/j.taap.2025.117625_bb0285","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1158\/1055-9965.EPI-15-0578","article-title":"Global cancer incidence and mortality rates and trends \u2013 an update","volume":"25","author":"Torre","year":"2016","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"issue":"1","key":"10.1016\/j.taap.2025.117625_bb0290","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1089\/ten.tec.2023.0199","article-title":"Patient-derived lung cancer \u201cSandwich cultures\u201d with a preserved tumor microenvironment","volume":"30","author":"Wang","year":"2024","journal-title":"Tissue Eng. Part C Methods"},{"issue":"6","key":"10.1016\/j.taap.2025.117625_bb0295","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1038\/bjc.2014.402","article-title":"Tumour cell proliferation (Ki-67) in non-small cell lung cancer: a critical reappraisal of its prognostic role","volume":"111","author":"Warth","year":"2014","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.taap.2025.117625_bb0300","doi-asserted-by":"crossref","first-page":"1229490","DOI":"10.3389\/fbioe.2023.1229490","article-title":"Establishing a three-dimensional scaffold model of hepatoblastoma","volume":"11","author":"Weigl","year":"2023","journal-title":"Front. Bioeng. Biotechnol."},{"issue":"12","key":"10.1016\/j.taap.2025.117625_bb0305","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics13122115","article-title":"Biological models of the lower human airways-challenges and special requirements of human 3D barrier models for biomedical research","volume":"13","author":"Wiese-Rischke","year":"2021","journal-title":"Pharmaceutics"},{"issue":"2","key":"10.1016\/j.taap.2025.117625_bb0310","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1093\/biostatistics\/kxx069","article-title":"Estimation of clinical trial success rates and related parameters","volume":"20","author":"Wong","year":"2019","journal-title":"Biostatistics (Oxford, England)"},{"key":"10.1016\/j.taap.2025.117625_bb0315","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41392-019-0099-9","article-title":"The emerging treatment landscape of targeted therapy in non-small-cell lung cancer","volume":"4","author":"Yuan","year":"2019","journal-title":"Signal Transduct. Target. Ther."},{"issue":"6","key":"10.1016\/j.taap.2025.117625_bb0320","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1073\/pnas.0709662105","article-title":"The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP","volume":"105","author":"Yun","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"4","key":"10.1016\/j.taap.2025.117625_bb0325","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s11684-018-0656-6","article-title":"Epithelial-to-mesenchymal transition in cancer: complexity and opportunities","volume":"12","author":"Zhang","year":"2018","journal-title":"Front. Med."},{"key":"10.1016\/j.taap.2025.117625_bb0330","doi-asserted-by":"crossref","first-page":"849","DOI":"10.3389\/fphar.2018.00849","article-title":"Association of variability and pharmacogenomics with bioequivalence of Gefitinib in healthy male subjects","volume":"9","author":"Zhang","year":"2018","journal-title":"Front. Pharmacol."}],"container-title":["Toxicology and Applied Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041008X25004016?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041008X25004016?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T08:56:56Z","timestamp":1780909016000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041008X25004016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":66,"alternative-id":["S0041008X25004016"],"URL":"https:\/\/doi.org\/10.1016\/j.taap.2025.117625","relation":{},"ISSN":["0041-008X"],"issn-type":[{"value":"0041-008X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An intestinal matrix-based human lung cancer model reflects clinical data from gefitinib on dosage-dependent efficacy","name":"articletitle","label":"Article Title"},{"value":"Toxicology and Applied Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.taap.2025.117625","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"117625"}}